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Arginine-vasopressin (AVP) stimulates the redistribution of water channels, aquaporin-2
(AQP2) from intracellular vesicles into the plasma membrane of renal collecting duct
principal cells. By this AVP directs 10% of the water reabsorption from the 170 L of
primary urine that the human kidneys produce each day. This review discusses molecular
mechanisms underlying the AVP-induced redistribution of AQP2; in particular, it provides
an overview over the proteins participating in the control of its localization. Defects
preventing the insertion of AQP2 into the plasma membrane cause diabetes insipidus.
The disease can be acquired or inherited, and is characterized by polyuria and polydipsia.
Vice versa, up-regulation of the system causing a predominant localization of AQP2 in
the plasma membrane leads to excessive water retention and hyponatremia as in the
syndrome of inappropriate antidiuretic hormone secretion (SIADH), late stage heart failure
or liver cirrhosis. This article briefly summarizes the currently available pharmacotherapies
for the treatment of such water balance disorders, and discusses the value of newly
identifiedmechanisms controlling AQP2 for developing novel pharmacological strategies.
Innovative concepts for the therapy of water balance disorders are required as there is a
medical need due to the lack of causal treatments.
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INTRODUCTION
The kidney has multiple functions including excretion of toxins, control of blood pressure and pH.
One of its main functions is water reabsorption from primary urine. The kidney generates more
than 170 L of primary urine per day by ultrafiltration of the blood. This huge volume, mainly water,
of course needs to be reduced to prevent dehydration. Indeed, only around 1% of the volume is
excreted as urine. How does the kidney achieve this?
The functional unit of the kidney is the nephron, of which there are around 1–2 million
per kidney. A nephron is a tubular system consisting of several functionally distinct segments.
The initial unit is the glomerulus where the blood is filtered at a rate of ∼120ml/min into the
surrounding Bowman’s capsule. The filtrate flows from there through the proximal convoluted
tubule, the descending and ascending limb of Henle, the distal convoluted tubule, and the collecting
duct into the bladder. During the passage the volume of the filtrate is reduced and its composition
altered. As the final urine, the filtrate reaches the bladder where it is stored until it is cleared.
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RENAL WATER CHANNELS: EXPRESSION
PATTERN AND FUNCTIONS
The concentration of the filtrate is achievedmainly by aquaporins
(AQPs) that allow diffusion of water across membranes. The
water flow is driven by an osmotic gradient established by sodium
across the kidney.
There are 13 mammalian AQPs, AQP0-AQP12, that show
high structural similarity. They all contain six transmembrane
domains, which form a water pore characterized by a dual NPA
motif (Preston et al., 1992; Jung et al., 1994; Kosinska Eriksson
et al., 2013). All AQPs assemble into homotetramers. Nine AQPs
(AQP1-8 and AQP11) are expressed along the nephron with
distinct localization to particular segments (Table 1). Crucial
roles in water reabsorption from primary urine play AQP1-
4. AQP1 in the plasma membrane of epithelial cells facing
the lumen of the proximal tubule and descending limb of
Henle facilitates reabsorption of 80–90% of water from the
filtrate (Nielsen et al., 1993; Schnermann et al., 1998). The
ascending limb of Henle is impermeable for water due to the
lack of AQPs. From the distal convoluted tubule throughout
the collecting duct AQP3 and 4 are constitutively expressed
in the basolateral plasma membrane (Ecelbarger et al., 1995;
Terris et al., 1995). Thus the apical plasma membrane is water
impermeable. However, in the collecting duct the principal
cells additionally express AQP2. It resides on intracellular
vesicles under resting conditions. Stimulation of vasopressin V2
receptors (V2R) on the basolateral surface of the cells with
arginine-vasopressin (AVP) causes a redistribution of AQP2
predominantly into the apical plasma membrane (Figure 1).
The insertion facilitates water reabsorption of around 10%
of the water from the remaining filtrate (Fushimi et al.,
1993; Katsura et al., 1995; Nielsen et al., 2002). In total, the
reabsorption of water by AQPs accounts for the reduction
of the volume of the initial filtrate from 170 L to around
2–4 L/day of final urine that is on average excreted by an
adult.
This review focuses on mechanisms controlling the
localization of AQP2 and the value of such control mechanisms
as pharmacological targets in cardiovascular diseases.
AVP STIMULATES THE REDISTRIBUTION
OF AQP2 FROM INTRACELLULAR
VESICLES INTO THE PLASMA MEMBRANE
The modulation of the final 10% of water reabsorption
in the collecting duct fine-tunes body water homeostasis.
Osmoreceptors in the hypothalamus detect changes in blood
osmolality that arise, for example, from hypernatremia and
hypovolemia, and induce the release of the peptide hormone
AVP (antidiuretic hormone) (Verney, 1947; Hayashi et al., 1994).
AVP is synthesized in the hypothalamus as a preprohormone.
It is released to the pituitary gland and secreted from there to
stimulate renal collecting duct principal cells to retain water.
As a result, blood volume increases, osmolality decreases, and
osmoreceptor signaling declines.
The primary regulator of blood pressure is the renin-
angiotensin-aldosterone system (RAAS). Hypotension or
hypovolemia induce renin secretion from renal juxtaglomerular
cells. Renin converts angiotensin I (Ang I) to angiotensin II (Ang
II). AngII acts as a vasoconstrictor, and induces aldosterone
and AVP secretion to stimulate renal sodium and water
reabsorption. This increases blood volume and blood pressure.
As a counterpart natriuretic peptides are secreted by cardiac
myocytes upon hypervolemia-induced mechanical stretching of
the atrial (atrial natriuretic peptide, ANP) and ventricular (brain
natriuretic peptide, BNP) walls. The peptides have vasodilative,
natriuretic and diuretic effects to lower blood volume and
pressure.
At the molecular level, AVP binds to its cognate G protein-
coupled receptor, the V2R, which is located in the basolateral
plasma membrane of collecting duct principal cells (Figure 1).
The binding of AVP to V2R activates the stimulatory G protein,
Gs. Gs, in turn activates adenylyl cyclases AC3 and AC6 to
convert ATP to cyclic adenosine monophosphate (cAMP). One
of the effectors of cAMP is protein kinase A (PKA). It consists of
a dimer of regulatory subunits (RIα, RIβ, RIIα, or RIIβ) and two
catalytic subunits (Cα, Cβ, Cγ, or PrKX) each bound to one R
subunit. Upon binding of cAMP to two sites in the R subunits
PKA undergoes a conformational change and the C subunits
are released. The free, and now active C subunits phosphorylate
nearby targets. PKA phosphorylates serine 256 (S256) in the C
terminus of AQP2.
AQP2 undergoes a constitutive recycling: its trafficking
from intracellular vesicles into the plasma membrane and
endocytic retrieval to its intracellular storage site is in dynamic
equilibrium under resting conditions. The equilibrium is
shifted toward plasma membrane insertion by the AVP-induced
phosphorylation of S256 (Klussmann et al., 2000; Nedvetsky
et al., 2009; Moeller et al., 2011). The finding that upon
inhibition of endocytosis AQP2 accumulates in the apical plasma
membrane of cultured cells regardless of AVP stimulation or S256
phosphorylation emphasizes the importance of the recycling
pathway (Lu et al., 2004). It also shows that the redistribution of
AQP2 can be induced independently of PKA activation (Nejsum
et al., 2005). In addition to the phosphorylation status of S256 that
of at least three further C-terminal residues of AQP2 changes in
response to AVP stimulation (Fushimi et al., 1997; Katsura et al.,
1997; Kamsteeg et al., 2000; Tamma et al., 2010): S261, S264, and
S269. S261 is phosphorylated under resting conditions and found
intracellularly; AVP triggers its dephosphorylation (Hoffert et al.,
2007). In contrast, AVP induces the phosphorylation of S264 and
S269 and thereby confers plasma membrane retention properties




Several proteins participating in the control of the localization
and functioning of AQP2 at various levels have been identified
(Table 2). They include, for example, proteins directing
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TABLE 1 | Renal aquaporins.
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Hara-Chikuma and Verkman,
2006; Wang et al., 2008; Kim
et al., 2011b; Arrighi and Aralla,
2014















Fushimi et al., 1993; Nielsen and
Agre, 1995; Nelson et al., 1998;
Merves et al., 2000; Rojek et al.,
2006; Kim et al., 2011b; Arrighi
and Aralla, 2014


















Echevarria et al., 1994; Ishibashi
et al., 1994; Ecelbarger et al.,
1995; Ma et al., 2000, 2002;
Hara et al., 2002; Kwon et al.,
2002; Roudier et al., 2002; Kim
et al., 2011b
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Hasegawa et al., 1994; Ma et al.,
1994, 1997; Yang et al., 1997;
Manley et al., 2000; Li and
Verkman, 2001; Zelenina et al.,
2002; Hiroaki et al., 2006; Ho
et al., 2009





















Raina et al., 1995; He et al.,
1997; Ishida et al., 1997; Ma
et al., 1999; Mhatre et al., 1999;
Ma et al., 2000; Krane et al.,
2001a,b; Song and Verkman,
2001; Nejsum et al., 2002; Kim
et al., 2011b; Procino et al.,
2011b; Wu et al., 2013










– Ma et al., 1996; Yasui et al.,
1999a,b; Ohshiro et al., 2001;
Ikeda et al., 2002; Liu et al.,
2005; Yasui, 2009; Kim et al.,
2011b











Ishibashi et al., 1997a, 2000a;
Kishida et al., 2000; Nejsum
et al., 2000; Liu et al., 2002;
Hara-Chikuma et al., 2005;
Hibuse et al., 2005; Sohara
et al., 2005, 2006a; Laforenza
et al., 2013











Ishibashi et al., 1997b; Elkjaer
et al., 2001; Yang et al., 2005;
Bienert et al., 2007; Saparov
et al., 2007; Kobayashi and
Yasui, 2010; Tamma et al.,
2011b
(Continued)
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TABLE 1 | Continued
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Ishibashi et al., 2000b; Morishita
et al., 2004, 2005b; Gorelick
et al., 2006; Ishibashi, 2006;
Yakata et al., 2007; Larsen et al.,
2010; Yeung and Cooper, 2010
AQPap, AQP adipose; AQP2L, AQP2 like; CD-aIC, collecting duct a-intercalated cells; CD-bIC, collecting duct b-intercalated cells; CD-PC, collecting duct principal cells; Class I, classical
aquaporins; Class II, aquaglyceroporins; Class III, superaquaporins, unorthodox AQPs, subcellular AQPs; CNT, connecting tubule; DL, descending limb of Henle; ER, endoplasmatic
reticulum; GLIP, glucagon-like insulinotropic peptide; HKID, original name of the clone (Ma et al., 1996); KO, knock out; MIP, major intrinsic protein; MIWC, mercurial-insensitive water
channel; PM, plasma membrane; PT, proximal tubule; SSC1, small solute channel 1; WCH4, water channel 4.
FIGURE 1 | Model of the arginine-vasopressin (AVP)-stimulated AQP2 translocation from intracellular vesicles into the plasma membrane of renal
collecting duct principal cells. The plasma membrane insertion of AQP2 facilitates water reabsorption from hypoosmotic primary urine. The exocytosis-like process
requires PKA phosphorylation of AQP2 at S256. Water exits the cells through water channels AQP3 and 4 constitutively expressed in the basolateral plasma
membrane. For details please refer to section Proteins controlling AQP2 trafficking.
exo- and endocytic trafficking, cytoskeletal proteins as
the tracks for the trafficking, proteins controlling cAMP
signaling such as A-kinase anchoring proteins (AKAPs) and
phosphodiestereases (PDEs). A few examples are discussed
below.
AKAPs
AKAPs are scaffolding proteins. They tether PKA in close
proximity of its substrates (Skroblin et al., 2010; Langeberg
and Scott, 2015). Global inhibition of AKAP-PKA interactions
in a cell culture model of renal principal cells, primary
inner medullary collecting duct (IMCD) cells, revealed that
AKAP-PKA interactions are crucial for the AVP-stimulated
translocation of AQP2 (Klussmann et al., 1999; Klussmann and
Rosenthal, 2001). AKAP18δ and AKAP220 are located on AQP2-
bearing vesicles to tether PKA in close proximity of AQP2. They
apparently facilitate the phosphorylation of S256 (Henn et al.,
2004; McSorley et al., 2006; Okutsu et al., 2008).
PDEs
Termination of cAMP signaling is achieved through hydrolysis
of cAMP by PDEs. There are 11 families of PDEs hydrolyzing
cAMP, cGMP, or both. PDE4 family isozymes are cAMP-
specific, constitutively active and shape local cAMP gradients,
thus regulating its availability for PKA activation (Houslay,
2010; Klussmann, 2015; Mika and Conti, 2015). PDE4D directly
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TABLE 2 | Proteins controlling AQP2 expression and/or localization.
Protein Suggested functional implication References
Actin Actin-depolymerization promotes AQP2 trafficking to the plasma membrane Simon et al., 1993; Umenishi et al., 2000;
Klussmann et al., 2001; Tamma et al.,
2001; Noda et al., 2004b, 2005, 2008
AKAP18δ AKAP18δ tethers PKA to AQP2-bearing vesicles, most likely facilitating its PKA phosphorylation Henn et al., 2004
AKAP220 AKAP220 tethers PKA to AQP2-bearing vesicles, most likely facilitating its PKA phosphorylation Okutsu et al., 2008
Annexin Annexin II is required for AQP2 trafficking to and/or fusion with the plasma membrane; annexins II
and VI belong to a motor complex binding to AQP2; annexins I, II, IV, and V are located on
AQP2-bearing vesicles
Barile et al., 2005; Noda et al., 2005;
Tamma et al., 2008; Zwang et al., 2009
AP1/2 AP1/2 mediates clathrin-mediated endocytosis of AQP2 Barile et al., 2005; Bouley et al., 2006; Lu
et al., 2007
AP-1 AP-1 increases AQP2 transcription Yasui et al., 1997; Irarrazabal et al., 2008
BIP BiP selectively binds to phosphorylated AQP2; its functional implication regarding AQP2 is currently
unknown
Zwang et al., 2009; Cai et al., 2010
Calcineurin Calcineurin enhances AQP2 transcription and dephosphorylates AQP2 during GOLGI/vesicle
routing, allowing normal trafficking
Valenti et al., 2000; Jo et al., 2001; Gooch,
2006; Li et al., 2007; Rinschen et al., 2011
Calcitonin Calcitonin induces cAMP-dependent AQP2 trafficking to the plasma membrane Bouley et al., 2011
Caveolin Caveolin-1 was suggested to mediate AQP2 internalization Aoki et al., 2012
CDK CDK1 and CDK5 were shown to phosphorylate AQP2 at S261 Rinschen et al., 2010
Clathrin Clathrin forms coated pits for AQP2 endocytosis Strange et al., 1988; Verkman et al., 1988;
Katsura et al., 1995; Sun et al., 2002
COXII COXII is involved in renal prostanoid synthesis and its inhibition leads to enhanced AQP2 protein
abundance
Nørregaard et al., 2005, 2010, 2011;
Jensen et al., 2006, 2010; Kim et al.,
2008; Kortenoeven et al., 2011
CREB CREB and CREB-like transcription factors increase AQP2 transcription Hozawa et al., 1996; Matsumura et al.,
1997; Yasui et al., 1997; Umenishi et al.,
2006; Yu et al., 2009
CSNK CSNK phosphorylates S256 during GOLGI transition of AQP2 Brunati et al., 2000; Procino et al., 2003
Dynactin Dynactin is located on AQP2-bearing vesicles and probably links them to the dynein complex Marples et al., 1998
Dynamin Dynamin binds to AQP2 and is involved in the scission of clathrin-coated AQP2-bearing vesicles
during endocytosis
Sun et al., 2002; Lu et al., 2004, 2007;
Barile et al., 2005; Moeller et al., 2010
Dynein Dynein mediates the microtubule-associated transport of endocytotic AQP2-bearing vesicles Marples et al., 1998; Vossenkämper et al.,
2007
EPAC Epac triggers AQP2 translocation to the plasma membrane Ca2+-dependently Umenishi et al., 2006; Yip, 2006;
Kortenoeven et al., 2012b
ERK ERK1/2 increases AQP2 transcription via the cAMP/Epac/ERK/CREB pathway; ERK1/2 may
mediate S256 phosphorylation under hypertonic conditions; ERK1/2 phosphorylates S261 in vitro
Bustamante et al., 2005; Hoffert et al.,
2006; Umenishi et al., 2006; Nielsen et al.,
2008a; Hasler et al., 2008b; Rinschen
et al., 2010
GSK3β GSK3β enhances PGE2 production by stimulation of COXII, which causes endocytic retrieval of
AQP2; GSK3β inhibition was suggested to reduce AVP-induced AC activity
Rao et al., 2005, 2010; Brown et al.,
2008; Nielsen et al., 2008b
HSC70,
HSP70
Hsc70 and Hsp70 are involved in clathrin-mediated endocytosis of AQP2, were shown to bind
AQP2 and suggested to affect AQP2 trafficking to the plasma membrane
Lu et al., 2007; Zwang et al., 2009;
Moeller et al., 2010; Rice et al., 2012; Park
et al., 2013
(Continued)
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TABLE 2 | Continued
Protein Suggested functional implication References
Integrin Integrins α1, α2, α5, and β1 are located on AQP2-bearing vesicles; Integrins α5 and β1 bind to
AQP2; Interaction of AQP2 with Integrin β1 promotes renal epithelial cell migration and might
regulate AQP2 trafficking via cAMP and Ca2+
Barile et al., 2005; Wu et al., 2009; Tamma
et al., 2011a; Chen et al., 2012
JNK JNK1/2 may mediate phosphorylation of S261 and S256 Hasler et al., 2008b; Nielsen et al., 2008a;
Rinschen et al., 2010
LIP5 LIP5 interacts with AQP2 and facilitates its lysosomal degradation van Balkom et al., 2009; Boone et al.,
2010
MAL MAL attenuates AQP2 internalization Kang et al., 2004; Kamsteeg et al., 2007
MLCK MLCK phosphorylates myosin regulatory light chain (MLC) and facilitates apical sorting of AQP2 by
regulating actin filament organization
Chou et al., 2004
Moesin Moesin was suggested to support the transport of AQP2 to the plasma membrane by modulating
actin depolymerization
Tamma, 2005
MUNC18b Munc18b inhibits fusion of AQP2-bearing vesicle to the plasma membrane by counteracting
SNARE complex formation
Procino et al., 2008
Myosin Myosins and associate proteins were localized on AQP2-bearing vesicles and/or bind to AQP2,
Myosin regulatory light chain might facilitate apical sorting of AQP2 by actin reorganization
Chou et al., 2004; Barile et al., 2005;
Noda et al., 2005; Nedvetsky et al., 2007
NFκB NFκB reduces AQP2 gene transcription Hasler et al., 2008a; Hocherl et al., 2010;
Hasler, 2011
p38-MAPK p38-MAPK phosphorylates AQP2-S261 that is associated with ubiquitination and proteasomal
degradation of AQP2
Hoffert et al., 2006; Brown et al., 2008;
Hasler et al., 2008b; Nedvetsky et al.,
2010; Rinschen et al., 2010
PI3K PI3K potentiates AVP-mediated increase of AQP2 expression; PI3K mediates endosomal retrieval of
AQP2-bearing vesicles
Tajika et al., 2004; Bustamante et al.,
2005; Pisitkun et al., 2008
PKA PKA phosphorylates AQP2-S256 and induces its trafficking to the apical plasma membrane Kuwahara et al., 1995; Lande et al., 1996;
Fushimi et al., 1997; Katsura et al., 1997;
Nishimoto et al., 1999; Kamsteeg et al.,
2000
PKB PKB- inhibits GSK3β, which increases the COX-mediated PGE2-production, resulting in reduced
AQP2 membrane abundance; PKB inhibits Akt substrate of 160 kDa (AS160), which was suggested
to increase plasma membrane abundance of AQP2
Bustamante et al., 2005; Nielsen et al.,
2008a; Pisitkun et al., 2008; Jung and
Kwon, 2010; Kim et al., 2011a
PKC PKC induces short-chain ubiquitination of AQP2, leading to its endocytosis and degradation; PKC
activation leads to depolymerization of α-tubulin and intracellular localization of AQP2; PKC was
suggested to maintain AQP2 transcription by phosphorylation of CREB, PKC is suggested to
phosphorylate S256 and S264
van Balkom et al., 2002; Hoffert et al.,
2006; Kamsteeg et al., 2006, 2008;
Brown et al., 2008; Bagnasco, 2012;
Douglass et al., 2012; Thai et al., 2012;
Zhao et al., 2012
PKG PKG was suggested to phosphorylate AQP2-S256, thus increasing its plasma membrane
abundance; PKG was suggested to inhibit AVP-dependent AQP2 trafficking by atrial natriuretic
peptide (ANP)
Bouley et al., 2000; Brown et al., 2008;
Klokkers et al., 2009
PP1/PP2A PP1 and PP2A inhibition induces AQP2 redistribution to the apical plasma membrane; PP1 binds to
AQP2
Valenti et al., 2000; Zwang et al., 2009
RAB RAB GTPases are located on AQP2-bearing vesicles and regulate its endosomal trafficking Liebenhoff and Rosenthal, 1995; Barile
et al., 2005; Tajika et al., 2005; Nedvetsky
et al., 2007; Vossenkämper et al., 2007;
Procino et al., 2011a
(Continued)
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TABLE 2 | Continued
Protein Suggested functional implication References
RAN RAN binds to AQP2 but its significance regarding AQP2 control is not known Zwang et al., 2009
RhoA RhoA stimulates actin-polymerization, which inhibits AQP2 trafficking to the plasma membrane Klussmann et al., 2001; Tamma et al.,
2001; Tamma, 2003
SNAP SNAP23 and SNAP25 are located on AQP2-bearing vesicles and participate in SNARE complex
formation during vesicle and plasma membrane fusion
Inoue et al., 1998; Shukla et al., 2001
SPA-1 SPA-1 binds to AQP2 and stimulates AQP2 trafficking to the apical plasma membrane Noda et al., 2004a
Synaptotagmin Synaptotagmin-13 is located on AQP2-bearing vesicles and might be involved in SNARE complex
formation during vesicle and plasma membrane formation
Kishore et al., 1998; Barile et al., 2005
Syntaxin Syntaxins are involved in SNARE complex formation during fusion of AQP2 vesicle and plasma
membrane; syntaxins 1A, 2, 3 and 4 are located in the plasma membrane of kidney epithelial cells,
syntaxins 5A, 7, 12, 13 and 16 are located on AQP2-bearing vesicles
Mandon et al., 1996, 1997; Gouraud,
2002; Brooks et al., 2003; Barile et al.,
2005; Procino et al., 2008; Mistry et al.,
2009
TM5b α-TM5b binds to AQP2, which results in F-actin destabilization and facilitates apical sorting of AQP2 Barile et al., 2005; Noda et al., 2005,
2008; Li et al., 2009b; Park et al., 2013
TONEBP TonEBP increases AQP2 transcription during hypertonic stress response Storm et al., 2003; Lam et al., 2004;
López-Rodríguez et al., 2004; Hasler
et al., 2006; Li et al., 2007; Hasler, 2011
TRPC3 TRPC3 interacts and translocates with AQP2 upon AVP stimulation, its functional implication is
presently unknown
Goel et al., 2007, 2010
TRPV4 TRPV4 interacts with AQP2, the functional implication is presently unknown Galizia et al., 2012
Tubulin α- and β-tubulin are located on AQP2-bearing vesicles; tubulin forms microtubules, which
participate in AVP-elicited apical sorting of AQP2-bearing vesicles and perinuclear positioning of
AQP2 after endocytosis
Sabolic et al., 1995; Breton and Brown,
1998; Marples et al., 1998; Shaw and
Marples, 2002; Kang et al., 2004; Barile
et al., 2005; Tajika et al., 2005;
Vossenkämper et al., 2007; Zhao et al.,
2012; Yui et al., 2013
Ubiquitin Ubiquitination at AQP2-K270 mediates AQP2 endocytosis and regulates its proteasomal
degradation
Barile et al., 2005; Kamsteeg et al., 2006;
Lee and Kwon, 2009; Boone et al., 2011;
Lee et al., 2011
VACM-1 VACM-1 targets E3 ligase formation and decreases AQP2 protein abundance Lee et al., 2011; Le et al., 2012
VAMP VAMP2 and 3 are located both on AQP2-bearing vesicles and in the plasma membrane and are
involved in SNARE complex formation during vesicle and plasma membrane fusion; VAMP8 was
suggested to be located on AQP2-bearing vesicles and to be implicated in SNARE complex
formation
Franki et al., 1995; Jo et al., 1995;
Liebenhoff and Rosenthal, 1995; Marples
et al., 1995; Nielsen et al., 1995;
Inoue et al., 1998; Gouraud, 2002; Barile
et al., 2005; Procino et al., 2008; Wang
et al., 2010
Several proteins were shown to regulate AQP2 expression, abundance, subcellular localization, and degradation. Listed proteins act downstream of receptor activation. For most
of them indirect evidence supports their role in AQP2-mediated water reabsorption. AKAP, A-kinase anchor protein, AKAP18δ/AKAP7δ, AKAP220/AKAP11; AP1/2, adaptor protein;
AP-1, activator protein; BIP/GRP78/HSP50-5/HSPA5/HSP70-5, Heat shock 70 kDa protein 5/Immunoglobulin heavy chain-binding protein/78 kDa glucose-regulated protein precursor;
Calcineurin, Protein phosphatase 2B, PP2B; CSNK, Golgi casein kinase, casein kinase; CDK, Cyclin-dependent kinase; COX, Cyclooxygenase-2; CREB, Cyclic AMP responsive element
binding protein; EPAC, Exchange protein activated by cAMP; ERK, Extracellular signal-regulated kinase,ERK1/MAPK3, ERK2/MAPK1; GSK3B, Glycogen synthase kinase 3β; HSC, Heat
shock cognate; HSP, Heat shock protein; JNK, c-Jun NH2-terminal kinase; LIP5, Lysosomal trafficking regulator interacting protein-5; MAL, Myelin and lymphozyte associated protein,
JNK1/MAPK8, JNK2/MAPK9; MAPK, mitogen activated protein kinase; MLCK, Myosin light chain kinase; Moesin, part of ERM (ezrin/radixin/moesin) protein compex; Munc18b,
Unc18-2, Syntaxin-binding protein 2; NFκB, Nuclear factor “kappa-light-chain-enhancer” of activated B-cells; P38-MAPK, p38 mitogen activated protein kinase, MAPK14; PI3K,
Phosphoinositide-3-kinase, MAPK14; PKA/B/C/G, Protein kinase A/B/C/G; PP1, Serine/threonine-proteine phosphatase 1; PKB/AKT; RAB, Ras-related protein; RAN, Ras-related
nuclear protein; RHOA, Ras homolog family member A; SNAP, Synaptosomal-associated protein 25; SPA-1, Signal-induced proliferation-associated protein 1; TM5b, α-Tropomyosin
5b; TONEBP, tonicity-responsive enhancer binding protein/NFAT5, Nuclear factor of activated T-cells 5/OREBP, Osmotic respone element binding protein; TRPC3, Transient receptor
potential cation channel subfamily C member 3; TRPV4, Transient receptor potential cation channel subfamily V member 4; VACM, Vasopressin-activated calcium mobilizing, Cullin 5;
VAMP2, Vesicle associated membrane protein/Synaptobrevin; VAMP3, Vesicle associated membrane protein/Cellubrevin.
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interacts with AKAP18δ on AQP2-bearing vesicles (Stefan et al.,
2007). The presence of PDE4D on AQP2-bearing vesicles
prevents an inappropriate plasma membrane insertion of AQP2
and thus water reabsorption in resting IMCD cells. Specific PDE4
inhibition with rolipram did not induce, but enhance the cAMP-
stimulated AQP2 translocation into the plasma membrane
(Stefan et al., 2007; Szaszák et al., 2008). On the other hand,
hyperactive PDE4 diminishes intracellular cAMP and causes
AVP resistance in amousemodel (Valtin et al., 1990; Takeda et al.,
1991).
Cytoskeletal Components
AQP2 is folded and assembled into homotetramers in the
endoplasmic reticulum (ER), passes through the Golgi and is then
stored in intracellular vesicles in the perinuclear region. Under
resting conditions, AQP2 binds monomeric G-actin (Noda et al.,
2004b, 2008). PKA-mediated AQP2 phosphorylation of S256
weakens the interaction. This increases the affinity of AQP2 to the
actin-stabilizing protein tropomyosin-5b, withdrawing it from
F-actin. Consequently, actin depolymerizes, enabling the vesicle
redistribution to the plasma membrane (Noda et al., 2008). AVP-
stimulated AQP2 vesicle trafficking to the plasma membrane
depends on F-actin depolymerization (Simon et al., 1993).
Activation of the small GTPase RhoA induces F-actin-containing
stress fibers and tonically inhibits AQP2 trafficking (Klussmann
et al., 2001; Tamma et al., 2001). Activated PKA phosphorylates
and thereby inhibits RhoA (Lang et al., 1996; Dong et al.,
1998), contributing to the AVP-induced destabilization of the
actin network. A role of actin in the redistribution of AQP2
is supported by observations in cultured renal collecting duct
cells (CD8 cells) treated with the serine/threonine phosphatase
1 and 2a inhibitor, okadaic acid. The agent increased the AQP2
phosphorylation of AQP2 at S256 by around 60% and led to
a depolymerization of the actin network. These findings also
supported the notion that the redistribution of AQP2 is not
exclusively controlled by PKA (Valenti et al., 2000).
SNAREs
The plasma membrane insertion of AQP2 occurs in an
exocytosis-like manner involving the SNARE (soluble N-
ethylmaleimide sensitive factor attachment protein receptor)
machinery (Liebenhoff and Rosenthal, 1995; Gouraud, 2002).
The vesicle-associated membrane proteins (VAMP) 2 and 3
reside on AQP2-bearing vesicles. They interact with apical
plasma membrane-located syntaxin 3 and the synaptosome-
associated protein (SNAP) 23 to achieve vesicle fusion and the
insertion of AQP2 into plasma membrane (Barile et al., 2005;
Procino et al., 2008).
Proteins for AQP2 Endocytosis and
Recycling
Adjustment of body water balance by AQP2-mediated
water reabsorption leads to a decline of AVP, followed by
internalization of AQP2. AQP2 retrieval from the plasma
membrane proceeds via clathrin-mediated endocytosis (Sun
et al., 2002). AVP stimulates co-accumulation of Hsc70 and
AQP2 in the apical plasma membrane (rat kidney sections), and
functional Hsc70 is required for AQP2 endocytosis in LLC-PK1
cells stably expressing AQP2. AQP2 directly interacts with the
endocytotic proteins clathrin, dynamin, and the adaptor protein
AP2 (Lu et al., 2007). The phosphomimic mutants S256D and
S269D of AQP2 show reduced interactions with the endocytotic
machinery, which reduces internalization and increases half-life
due to decreased proteasomal degradation (Moeller et al., 2010).
Myelin and lymphocyte-associated protein (MAL), a protein
found in glycosphingolipid-enriched membranes and potentially
involved in the apical transport machinery forms a complex with
AQP2 in LLC-PK1 cells (Frank et al., 1998; Martín-Belmonte
et al., 2000; Kamsteeg et al., 2007). As phosphorylation of S256
strengthens the interaction withMAL andMAL attenuates AQP2
internalization, this is in line with the above-described reduced
endocytosis to explain the stabilization and accumulation of
pS256 in the apical plasma membrane.
From the plasma membrane AQP2 is recycled or directed
for degradation. The motor protein myosin Vb, its receptor on
AQP2-bearing vesicles, Rab11, and the adaptor protein Rab11-
FIP2 are essential for recycling through the Rab11-dependent
recycling pathway (Nedvetsky et al., 2007). Positioning of AQP2-
bearing vesicles in their perinuclear storage region involves
microtubules (Vossenkämper et al., 2007).
Ubiquitin
Under resting conditions AQP2 is phosphorylated at S261
by, amongst others p38 MAP kinase (Nedvetsky et al., 2010).
The phosphorylation is a signal for AQP2’s mono- and
poly-ubiquitination. The short-chain ubiquitination of AQP2
at K270 increases its endocytosis under resting conditions
(Kamsteeg et al., 2006). In primary IMCD cells, AVP causes
a decrease in the phosphorylation of S261 within 30min
of exposure. This reduces polyubiquitination and prevents
AQP2’s proteasomal degradation resulting in an increase in its
abundance. Thus, AQP2 expression adapts quickly to water
availability: thirsting increases, whereas water overload reduces
AQP2 levels (Nedvetsky et al., 2010). The AVP-induced reduction
of polyubiquitination of AQP2 implies that its recycling via the
Rab11 pathway requires its deubiquitination.
AQP2 short-chain ubiquitination and subsequent
internalization can occur independently of the AVP-PKA
axis upon activation of protein kinase C (PKC) (Han et al., 1994;
van Balkom et al., 2002; Kamsteeg et al., 2006). Prostaglandin
2 (PGE2) or dopamine counteract AVP and induce AQP2
retrieval from the apical plasma membrane (Zelenina et al., 2000;
Edwards and Brooks, 2001). The underlying pathway is not fully
elucidated. In addition to PKC it may involve modulation of the
ubiquitination of AQP2 (Hébert et al., 1990; Tamma et al., 2003b;
Nejsum et al., 2005).
DYSREGULATION OF AVP-MEDIATED
WATER REABSORPTION CAUSES WATER
BALANCE DISORDERS
Several diseases are associated or caused by dysregulation of
AVP-mediated water reabsorption (Figure 2). Elevated levels of
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FIGURE 2 | Water balance disorders. (A) Diabetes insipidus describes the abnormal loss of hypoosmotic urine (polyuria) along with increased thirst (polydipsia).
The antidiuretic peptide hormone arginine-vasopressin (AVP) is synthesized in the hypothalamus as a prohormone. Mature AVP is secreted from the neurohypophysis
to stimulate the kidneys to retain water. Mutations in the AVP gene impede correct processing or reduce its affinity for the V2 receptor, which precludes AVP-mediated
water reabsorption from primary urine and is termed central diabetes insipidus (CDI). In the rare case of gestational diabetes insipidus, placenta-released
vasopressinase degrades AVP, counteracting antidiuretic signaling. Similarly, mutations in the gene encoding the V2 receptor (AVPR2) render renal principal cells
(Continued)
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FIGURE 2 | Continued
AVP-resistant. Defects in AQP2 protein expression, channel function, intracellular sorting, or membrane translocation disrupt the responsiveness of principal cells to
antidiuretic stimuli and maintains low water permeability of the kidney collecting duct. (B) Deregulated accumulation of AVP enhances antidiuretic stimulation of renal
principal cells through the V2 receptor and triggers enhanced AQP2-conducted water reabsorption from the primary urine urine (SIADH, heart failure, liver cirrhosis).
The same effect is caused by a mutation in the AVPR2 gene constitutively activating the receptor. Both defects abnormally elevate water retention.
AVP as in the syndrome of inappropriate antidiuretic hormone
secretion (SIADH), late stage heart failure, and liver cirrhosis
cause excessive water retention. Defects preventing the insertion




Patients suffering from diabetes insipidus display a limited ability
to concentrate urine. This leads to polyuria and polydipsia
(Knoers, 1993; Bockenhauer and Bichet, 2015), and if untreated
to severe dehydration, hypernatremia, and hyperchloremia
(Multari et al., 2001; Qureshi et al., 2014).
Diabetes insipidus may be inherited or acquired. In central
diabetes insipidus (CDI) mutations in the gene encoding AVP
lead to insufficient amounts of AVP released from the pituitary
gland. The consequence is a compromised concentrating ability
of the collecting duct due to a low level of V2R stimulation
and abnormally low AQP2 levels, resulting from the lack of
AVP-dependent AQP2 gene expression (Ishikawa, 2000). The
prevalence of CDI is 1 in 25,000 (www.orpha.net). An animal
model reproducing CDI is the Brattleboro rat. The rats lack AVP
and the expression levels of AQP2 are decreased (Sokol and
Zimmerman, 1982; Kishore et al., 1996).
Mutations in the V2R gene (X-chromosome, Xq28) cause X-
linked NDI, which accounts for ∼90% of all congenital NDI
forms (Peters et al., 2007; Heinke and Labudde, 2012). Due to
the lack of a functional V2R gene, the AQP2 level is decreased
and AQP2 does not translocate into the plasma membrane. The
prevalence of X-linked NDI is 3.7 in 1 million males (Bichet et al.,
1992). Interestingly, in the Canadian province Nova Scotia the
incidence is much higher with 58 in 1 million male live births,
a founder effect discussed as the “Hopewell hypothesis” (Bichet
et al., 1993; Arthus et al., 2000). The X-linked inheritance is
obviously more apparent in males due to the lack of a second X
chromosome. Even after administration of dDAVP (see below)
the male patients do not show signs of improvement (Knoers and
Deen, 2001). An animal model reproducing the phenotype is the
inducible V2R knockout mouse model (Li et al., 2009a).
The remaining ∼10% of the persons with congenital
autosomal recessive and autosomal dominant forms of NDI carry
mutations in the AQP2 gene (Deen et al., 1994; Park et al.,
2014). Autosomal dominant forms were observed in patients
with frame shift mutations producing a C-terminally elongated
AQP2 protein (721delG/727delG) or a mutation leading to an
E258K substitution (Mulders et al., 1998; Kuwahara et al., 2001;
Marr et al., 2002b). When overexpressed in Xenopus oocytes, the
E258K, and AQP2-727delG versions were misrouted to the Golgi
and late endosomes, respectively (Mulders et al., 1998; Marr
et al., 2002b). The dominant-negative effect seems to be conferred
by the formation of heterotetramers with wild type AQP2 that
fail to translocate to the plasma membrane in response to AVP
(Marr et al., 2002b). Disruption of the PKA consensus sequence
by the substitution R254L interferes with the AVP-induced
PKA phosphorylation of S256 and also leads to autosomal
dominant NDI (de Mattia et al., 2005). The AQP2 version S256L,
associated with congenital progressive hydronephrosis, cannot be
phosphorylated and causes a severe urine concentration defect in
mice, underpinning the importance of S256 for controlling water
homeostasis (McDill et al., 2006).
Most of the more than 30 known AQP2 mutations associated
with hereditary nephrogenic diabetes insipidus cause autosomal
recessive NDI (Fujiwara and Bichet, 2005; Park et al., 2014; Cen
et al., 2015). The mutations predominantly cause ER retention
and impair protein stability and proper channel function (Deen
et al., 1995; Mulders et al., 1997; Goji et al., 1998; Marr et al.,
2002a). In comparison to the autosomal dominant mutants, the
recessive ones such as AQP2-R187C do not form heterotetramers
with wild type AQP2 (Kamsteeg et al., 1999).
There are several animal models available for studying AQP2
in the pathophysiology of NDI (Boone and Deen, 2009). Mice
globally lacking AQP2 or mice expressing the T126M mutant
die within 2 weeks of age (Yang et al., 2001; Rojek et al., 2006).
The collecting duct-specific knockout of AQP2 enabled survival.
In addition, mouse models with an amino acid substitution in
the PKA phosphorylation site (S256A; McDill et al., 2006), an
F204V substitution (Lloyd et al., 2005) or a complete deletion
of the C-terminus were established to study recessive NDI (Shi
et al., 2007). Sohara et al. presented the first mouse model for
autosomal-dominant NDI, in which the assembly of mutant with
wild type AQP2 into heterotetramers supported the in vitro
findings (Sohara et al., 2006b). Using this model the PDE
inhibitor rolipram was identified as a potential drug to treat
autosomal-dominant NDI.
The most common form of NDI is acquired NDI. One of
the main causes is the long-term treatment of bipolar disorders
with lithium. This causes acquired NDI in up to 40% of the
patients (Sim et al., 2014). In elderly patients a 6-year prevalence
rate of 3% was observed (Rej et al., 2014). The uptake route
of lithium into collecting duct principal cells is through the
epithelial sodium channel (ENaC). Lithium inhibits adenylyl
cyclases and thereby cAMP synthesis and, consequently, the
cAMP-dependent signaling that controls AQP2 trafficking and
expression. A marked decrease in AQP2 expression in human
and rat medullary collecting ducts has been reported with long-
term lithium carbonate treatment (Blount et al., 2010).
Gestational DI is another form of acquired NDI. It manifests
during pregnancy in the third trimester and in the early
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postpartum period. During pregnancy, the threshold level of
serum osmolality to induce AVP secretion is lowered. The
metabolic AVP clearance is increased due to increased levels of
the trophoblast-produced aminopeptidase vasopressinase, which
can lead to a transient form of DI (Barron et al., 1984; Durr
et al., 1987; Davison et al., 1989). Gestational DI has a prevalence
of 2–4 in 100,000 pregnancies and can be treated with dDAVP
(see below), as this AVP analog is resistant to degradation
by vasopressinase (Ananthakrishnan, 2009). Placental abruption
can cause acute postpartum DI owing to high amounts of
placental vasopressinase released into the circulation (Wallia
et al., 2013). Occurrence of gestational DI is elevated in women
with preeclampsia, HELLP syndrome (Hemolysis, Elevated Liver
enzymes, and Low Platelets) or liver steatosis. These conditions
present defective hepatic vasopressinase degradation (Katz and
Bowes, 1987; Usta et al., 1994; Ellidokuz et al., 2006).
Bilateral ureteral obstruction (BUO) can cause acquired NDI
with a marked decrease in AQP2 abundance (Jensen et al., 2009;
Radin et al., 2012). In a rat model, the AQP2 level drops to a
fourth of the control within 24 h upon induction of BUO and
the phosphorylation of S256 is decreased (Stødkilde et al., 2011).
Even 1 week after the release of BUO and when the urine output
had become normal, AQP2 levels reached only half those of the
controls. Upon dehydration, the affected rats were not able to
efficiently concentrate urine (Frøkiaer et al., 1996), indicating
that reduced levels of AQP2 are the main limiting factor during
recovery from polyuria caused by BUO.
Acquired NDI can also be caused by hypercalcemia
(Khairallah et al., 2007; Kamath et al., 2013), hypokalemia
(Celik et al., 2014), and secondary hyperaldosteronism (Lee et al.,





In SIADH, late stage heart failure, and liver cirrhosis elevated
levels of AVP lead to diluted plasma with hyponatremia with or
without hypervolemia. Hyponatremia is a physiological response
to maintain an adequate circulating blood volume but turns into
an electrolyte disorder when serum sodium drops to less than 135
mEq/L.
SIADH is the most frequent cause of hyponatremia,
accounting for approximately one-third of all cases (Ishikawa,
2015). The abundance and plasma membrane localization of
AQP2 is increased (Kortenoeven et al., 2013), which leads
to excessive water retention and hypervolemic (dilutional)
hyponatremia (Fenske and Allolio, 2010; Braun et al., 2015). A
mutation in the V2R gene that causes nephrogenic syndrome of
inappropriate antidiuresis (NSIAD) leads to constitutively active
receptors triggering SIADH-like symptoms without elevated
AVP levels (Feldman et al., 2005).
In humans with heart failure and in several animal models of
heart failure, RAAS system activity, the non-osmotic release
of AVP and the expression level and membrane localization
of AQP2 are significantly increased. The consequence is water
retention with increased circulatory blood volume (Radin et al.,
2012; Cui et al., 2015; Ishikawa, 2015). An excessive circulatory
volume results in hypervolemic hyponatremia. These patients
have a poor prognosis (Noveanu et al., 2011). However, recent
studies of heart failure in rat models revealed increased AQP2
protein abundance even in the presence of normal AVP and
unchanged plasma sodium levels (Hadrup et al., 2004). Thus in
heart failure AQP2 may be up-regulated more generally than
previously thought (Brønd et al., 2013).
Liver cirrhosis is associated with a non-osmotic AVP release,
water retention and hyponatremia (John and Thuluvath, 2015).
The NO concentration in the plasma of cirrhosis patients
correlates with the extent to which AQP2 levels are increased
(Chung et al., 2010). However, the underlying mechanisms
modulating water reabsorption through AQP2, and sodium
excretion are unknown (Wilson et al., 2013).
Nephrotic syndrome is similar to heart failure and liver
cirrhosis with regard to increased AVP levels and water retention
(Apostol et al., 1997; Bou Matar et al., 2012). In contrast to
heart failure and liver cirrhosis the nephrotic syndrome shows
an “escape” from AVP in the renal collecting ducts. This “escape
phenomena” is characterized by a notable down-regulation
of AQP2 expression despite high AVP levels. Water balance
disorders associated with “escape” phenomena are characterized
by an ability to prevent water retention and hyponatremia
via secondary natriuresis (Brønd et al., 2004; Verbalis, 2006).
A possible mechanism involved in the AVP “escape” includes
reduced V2 receptor binding and uncoupling of the V2 receptor
from its cognate G protein resulting in abnormally low cytosolic
cAMP concentrations upon dDAVP stimulation (Ecelbarger
et al., 1998; Tian et al., 2000; Jonassen et al., 2003; Brønd et al.,
2004).
ESTABLISHED PHARMACOLOGICAL
TREATMENTS OF DIABETES INSIPIDUS
AND NEW OPTIONS
Desmopressin (dDAVP)
CDI is commonly treated by the administration of an AVP
analog, desmopressin (dDAVP), for example, via a nasal spray
or infusion (van Balkom et al., 2004; Kortenoeven and Fenton,
2014). Chronic treatment with dDAVP increases the AQP2 level
in apical plasmamembranes of both cortical and inner medullary
collecting duct principal cells, and decreases urine output usually
drastically (Agarwal and Gupta, 2008; Kortenoeven and Fenton,
2014).
Diuretics
The main strategy for the treatment of X-linked NDI is to
bypass non-functional V2R and restore physiological expression
levels of AQP2 as well as AQP2 trafficking. Thiazides are widely
used in patients with NDI. They decrease urine volume, but the
mechanism by which they exhibit their paradoxical antidiuretic
effect is poorly understood (Kim et al., 2004a). It was proposed
that thiazides inhibit reabsorption of sodium and chloride in the
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distal collecting duct and thus increase the osmolality of the urine
(Bockenhauer and Bichet, 2014).
Hydrochlorothiazide (HCTZ) combined with amiloride is the
main therapy in patients with lithium-induced NDI (Sinke et al.,
2014). Treatment with thiazides can decrease the glomerular
filtration rate, which causes a reduced excretion of lithium,
resulting in lithium intoxication. Amiloride, a potassium sparing
diuretic, interferes with lithium uptake by blocking ENaC, and
for this reason is combined with thiazides (Bedford et al.,
2008; Kishore et al., 2015). Also a combination of HCTZ with
the NSAID, indomethacin (see below) reduces urine output
more effectively than the administration of thiazides alone
(Kortenoeven and Fenton, 2014). The expression of AQP2 was
substantially reduced in the collecting ducts of lithium-treated
rats and was increased in the presence of amiloride (Bedford
et al., 2008).
Statins
Statins are lipid-lowering drugs used to reduce cardiovascular
risks. They competitively inhibit hepatic 3-hydroxy-3-
methylglutaryl-coenzyme A reductase catalyzing the conversion
of HMG-CoA to mevalonate. Thereby statins inhibit the
production of isoprenoid intermediates such as farnesyl
pyrophosphate (FPP), geranylgeranyl pyrophosphate (GGPP).
A range of proteins undergoes post-translational modifications
by addition of isoprenoid pyrophosphates (Verhulst et al., 2004).
FPP and GGPP act as lipid anchors required for membrane
tethering and activation of heterotrimeric G proteins and small
GTPases, amongst them RhoA (Li et al., 2011; Szygula-Jurkiewicz
et al., 2014). Statins inhibit RhoA isoprenylation, leading to the
accumulation of inactive RhoA in the cytoplasm (Liao and Laufs,
2005).
In MCD4 cells, mouse collecting duct cells stably expressing
AQP2, statins inhibit the isoprenylation and thus activation of
RhoA (Procino et al., 2010). This causes F-actin depolymerization
and an AVP-independent increase in AQP2 plasma membrane
localization (Bouley et al., 2008; Procino et al., 2010, 2011a; Li
et al., 2011; Wade, 2011). Statins also activate the NO/cGMP
pathway (Tamma et al., 2003a; Rikitake and Liao, 2005; Maher
et al., 2009) and thus may induce AQP2 phosphorylation at S256
and thereby induce the insertion into the plasma membrane.
Incubation of LLC-PK1 and MCD4 cells with simvastatin
resulted in AQP2 plasma membrane accumulation in a dose-
dependentmanner due to reduced clathrin-mediated endocytosis
(Procino et al., 2012). Short-term exposure to simvastatin
produced no change in cholesterol plasma membrane levels,
but increased AQP2 accumulation in the apical membrane
of principal cells in Brattleboro rats. This increased water
reabsorption and urine concentration (Li et al., 2011; Bonfrate
et al., 2015). In adult Munich-Wistar male rats subjected to
BUO for 2 h atorvastatin improved urinary concentrating ability
by reversing ureteral obstruction-induced down-regulation of
AQP2 (Danilovic et al., 2012). Fluvastatin increased AQP2
plasma membrane abundance in wild-type mice. In the same
study when X-linked NDI mice were treated with secretin
plus fluvastatin, urine volume was reduced by nearly 90% and
the urine osmolality was doubled. Fluvastatin promoted AQP2
trafficking to the plasma membrane whereas secretin increased
intracellular stores of AQP2 (Procino et al., 2014). Additional
experiments in mice indicated that fluvastatin increases AQP2
membrane accumulation by altering the prenylation status of
key proteins regulating AQP2 trafficking such as RhoA (Procino
et al., 2011a).
In a recent study, 24 naïve hypercholesterolemic patients
were treated with simvastatin (20mg/day for 12 weeks). This
rapidly and significantly enhanced urine excretion of AQP2, and
decreased the 24 h diuresis while urine osmolality increased. This
occurred similarly and persistently in patients who were treated
with statins in the long-term, i.e., for at least 1 year (Procino et al.,
2015).
Collectively, the data suggest that statins provide novel
opportunities for the treatment of X-linked NDI as their target
is independent from V2R.
Prostaglandins
Prostaglandin E2 (PGE2) is synthesized and released in the
collecting duct (Olesen et al., 2011). It is one of the
major cyclooxygenated metabolites of arachidonic acid that
stimulates all four G protein-coupled E-prostanoid receptors,
EP1-EP4 (Hao and Breyer, 2008). PGE2/EP1 signaling elicits
a diuretic response via the Gαq-mediated activation of PKC,
triggering AQP2 internalization (Bachteeva et al., 2007).
However, an EP1-mediated decrease in AQP2-induced water
permeability was only observed in frog urinary bladder, but
not in collecting ducts (Bachteeva et al., 2007). EP3 is
coupled to Gαi and reduces cAMP synthesis upon activation
(Sugimoto et al., 1992), thus decreasing AQP2 expression and
membrane localization (Zelenina et al., 2000). EP3-signaling also
stimulates RhoA (Tamma et al., 2003b), probably mediated by
the Gα12/13-dependent activation of Rho guanine nucleotide
exchange factors (GEFs) (Yamaguchi et al., 2000; Wells et al.,
2002). GEFs directly activate RhoA and thus attenuate AQP2
membrane trafficking (Klussmann et al., 2001; Tamma et al.,
2001). The activation of the different signaling pathways
is most likely due to different EP3 splice variants (Namba
et al., 1993; Hatae et al., 2002). The observation of various
cellular responses might also be the result of the differential
expression of PGE2 receptors in model systems derived from
different renal sections of diverse species (Olesen and Fenton,
2013).
EP2 and EP4 couple to Gαs (Alexander et al., 2011).
The stimulation of each receptor results in the increased
phosphorylation of AQP2-S264, whose effect is presently
unknown (Olesen et al., 2011). Only EP2 signaling increases
the cytosolic cAMP concentration AVP-independently (Breyer
and Breyer, 2001) and stimulates the phosphorylation of
AQP2 at S256 and S269 (Olesen et al., 2011). However, there
are contradictory data on whether EP2 is expressed in the
collecting duct at all (Sugimoto et al., 1994; Breyer et al.,
1996; Morath et al., 1999; Jensen et al., 2001; Regan, 2003;
Hao and Breyer, 2008). EP4 is widely spread in the collecting
duct (Sugimoto and Narumiya, 2007). Its activation enhances
AQP2 membrane trafficking, although the cytosolic cAMP
concentration remains unaffected (Olesen et al., 2011). This
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might result from promiscuous G protein coupling (Fujino and
Regan, 2006) which may occur upon PKA phosphorylation
of EP4 (Olesen and Fenton, 2013). In line, EP4 activation
stimulates phosphatidylinositol 3-kinase (PI3K) (Fujino et al.,
2003), which is suggested to regulate AQP2 expression and
endosomal retrieval (Tajika et al., 2004; Bustamante et al., 2005).
Altogether, the molecular details of PGE2 signaling remain to be
completely understood.
Non-steroidal anti-inflammatory drugs (NSAIDs) block the
production of PGE2, other prostaglandins and thromboxanes
by inhibition of the cyclooxygenases, COX-1 and COX-2 (Jin,
2015). NSAIDs are commonly used in the treatment of pain and
inflammation. Their use in cell culture and animal models has
shed some light on the role of prostaglandins such as PGE2 in the
control of water homeostasis (Baggaley et al., 2010; Jia et al., 2012;
Kortenoeven et al., 2012a).
Recently, effects of the chronic use of the NSAIDs, ibuprofen
and meloxicam, on AQP2 were investigated in kidneys
from Sprague-Dawley rats. The daily application of the
drugs enhanced urine output and significantly reduced urine
osmolality after 7–14 days. In line, both drugs significantly
reduced the AQP2 protein abundance by 60–70%. Meloxicam
significantly increased AQP2 phosphorylated at S256 and
S261, whereas ibuprofen increased the AQP2 phosphorylated
at S256 but did not affect the phosphorylation of AQP2
at S261. Both ibuprofen and meloxicam increased the
phosphorylation of AQP2 at S264 and S269. The observed
alterations in the C-terminal phosphorylations of AQP2 may
partially compensate for the decrease in AQP2 abundance
by promoting its membrane localization and thereby
permitting only a limited effect on urine osmolality (Ren
et al., 2015).
Indomethacin enhances the antidiuretic activity of AVP and
markedly reduces urine output by increasing the AQP2 plasma
membrane insertion. This effect of indomethacin is additive with
that of thiazide diuretics (Kim et al., 2004b).
In a study where male Wistar rats were treated with
indomethacin, ibuprofen and meloxicam AQP2 expression
was significantly decreased in water-restricted rats but PGE2
excretion did not significantly change. This effect was less
pronounced in water-loaded rats and meloxicam had no
significant effect. The stronger effect of NSAIDs on the AQP2
protein level during water restriction seems most relevant for
elderly and severely ill patients who are prone to dehydration
(Baggaley et al., 2010; Lauridsen et al., 2010).
Stimulation of EP2 and EP4 increases AQP2 trafficking via
increased cAMP. The EP2 agonist, butaprost relieved symptoms
of NDI in a rat model (Gao et al., 2015; Olesen et al.,
2011). Pharmacological blocking of V2R in rats results in NDI,
which could be greatly mitigated via the administration of an
EP2 agonist. EP2 agonists are already used in the treatment
of dysmenorrhea (Moeller et al., 2013). Moreover, selective
EP4 agonists relieved NDI symptoms developed in V2R gene-
deficient mice (Bockenhauer and Bichet, 2014). In a mouse
model for X-linked NDI, an EP4 receptor agonist, [ONO-AE-
329 (ONO)] efficiently increased urine osmolality and reduced
polyuria.
Taken together a possible strategy for the treatment of NDI
might be the stimulation of EP2 and/or EP4 and simultaneous
blocking of EP3.
PGE2 is particularly important for lithium-induced diabetes
insipidus. Increased expression of COX-2 and abnormally high
urinary excretion of PGE2 has been noted in animal models
suffering from lithium-induced NDI. Lithium-treated patients
have elevated urine PGE2 excretion as well (Kim et al., 2008).
Administration of COX-2 inhibitors to adult mice and rats
relieved the lithium-associated polyuria. Indomethacin blocks
prostaglandin production in lithium-treated mpkCCD cells.
Additionally, PGE2 synthase-1 (mPGES-1)-deficient mice did
not develop lithium-associated polyuria (Jia et al., 2009; Baggaley
et al., 2010; Kjaersgaard et al., 2014). In clinical practice
inhibition of prostaglandin synthesis with NSAIDs remains an
effective therapy for lithium-induced NDI (Kortenoeven et al.,
2012a).
PDE Inhibitors
An increase in cGMP levels, e.g., by ANP or the nitric oxide
(NO) donor sodium nitroprusside activates protein kinase G
(PKG). PKG can phosphorylate AQP2 at S256 to induce
its redistribution into the plasma membrane (Bouley et al.,
2000). PDE5 specifically hydrolyses cGMP and thereby prevents
cGMP/PKG signaling. PDE5 is present in the principal cells of
the collecting duct along with further PDEs, including PDE1
and PDE4 (Dousa, 1999). Inhibition of PDE5, in particular with
sildenafil (Viagra) causes AQP2 plasma membrane accumulation
in LLC-PK1 cells. This effect was attributed to the activation
of the NO/cGMP pathway (Bouley et al., 2000, 2005) as
also sodium nitroprusside, L-arginine (a precursor of NO)
and ANP induce plasma membrane accumulation of AQP2
in vitro, and ANP also in vivo (Brown et al., 2012). In
line, mice deficient in NO synthase isoforms developed
NDI (Morishita et al., 2005a). PDE5 inhibitors and ANP
combined cause natriuresis and decreased urine output (Bouley
et al., 2005; Assadi and Ghane Sharbaf, 2015). Therefore,
the activation of AVP-independent cGMP signaling with
sildenafil could be an option in the treatment of X-linked
NDI as it bypasses the defective V2R/cAMP axis (Sanches
et al., 2012). Sildenafil is already used for the treatment of
erectile dysfunction, pulmonary hypertension and subarachnoid
hemorrhage.
The PDE4 family of enzymes (PDE4A, PDE4B, PDE4C,
and PDE4D) encodes more than 20 isozymes (Houslay, 2010;
Klussmann, 2015). Rolipram selectively inhibits the PDE4
isozymes by targeting the catalytic domain of the enzymes.
Rolipram enhances the AVP-induced accumulation of cAMP,
the translocation of AQP2 into the plasma membrane and
the osmotic water permeability of cultured IMCD cells (Stefan
et al., 2007). Moreover, rolipram increased urine osmolality in
a mouse model of autosomal dominant NDI (Sohara et al.,
2006b). However, the clinical trial with rolipram failed (Bichet
et al., 1990) because of its intolerable side effects, mainly nausea
and vomiting. Recently, roflumilast, and apremilast, both non-
selective inhibitors of PDE4A-D, with fewer side effects reached
the market. Roflumilast is approved for the treatment of chronic
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obstructive pulmonary disease (COPD) and apremilast for
psoriatic arthritis (Klussmann, 2015). These new PDE4 inhibitors
may provide a new opportunity for the therapy of X-linked NDI.
Pharmacological Chaperones
Cell-permeable pharmacological chaperons have proven their
efficacy in restoring the plasma membrane localization and
functional rescue of V2R. Vaptans (see below) not only block
the V2R but can also act as such chaperones. The cell-
permeable V2R antagonists S121463 and VPA-985 stabilize ER-
retained V2R mutants, so that the receptor can be released
from the ER and inserted into the plasma membrane (Morello
et al., 2000; Wüller et al., 2004). These positive effects of
pharmacological chaperons were reproducible in Madin-Darby
canine kidney (MDCK) cells overexpressing nine ER-retained
V2R mutants involved in NDI (Robben et al., 2006). SR49059
(Conivaptan), a non-selective blocker of V2R and vasopressin
V1a receptors (Bernier et al., 2004), has been tested in
NDI patients where it decreased urine output and was thus
suggested for the treatment of X-linked NDI (Bernier et al.,
2006). The chaperones are active in nanomolar concentrations
on cultured cells. Regarding NDI treatment the high affinity
OPC31260 (mozavaptan) and OPC41061 (tolvaptan) non-
peptidic antagonists would promise beneficial effects in terms
of V2R rescue, low doses and efficient substitution for AVP
(Robben et al., 2007; Wesche et al., 2012). On the other hand,
since low affinity antagonists require higher doses for clinical
efficacy this could lead to hepatic toxicity because of potential
interference with cytochrome P450 systems. Hence, further
studies using modified antagonists or treatment regimes are
required.
Vice versa, agonists binding to V2R mutants induced the
production of sufficient amounts of cAMP and the translocation
of AQP2 into the apical plasma membrane of renal cells.
Biased agonists of the V2R represent a novel therapeutic
strategy for the treatment of congenital NDI. The non-peptidic
agonists MCF14 (OPC23h), MCF18 (VNA932), and MCF57
are full agonist of the V2R but do not induce receptor
internalization and arrestin-associated signaling. From a clinical
perspective these properties can be of great importance as
they can have long-lasting effects (Mouillac and Mendre,
2014).
Both strategies with antagonists or agonists are not applicable
if V2R is not at least partially functional or if it is insensitive to
such agents (Moeller et al., 2013; Bockenhauer and Bichet, 2014).
Activators of the AQP2 Shuttle
An unbiased screening of 3646 compounds for stimulators of
the redistribution of AQP2 to the apical plasma membrane
of LLC-PK1 cells identified the JAK-2 and EGFR inhibitor
AG-490. The molecule induced the AQP2 accumulation
at the plasma membranes of LLC-PK1 and Madin-Darby
canine kidney (MDCK) cells and at that of principal
cells in rat kidney sections. AG-490 treatment of AVP-
deficient Brattleboro rats improved their urine concentrating
capacity within 2 h (Nomura et al., 2014; Sands and Blount,
2014).
PHARMACOLOGICAL TREATMENTS OF
WATER BALANCE DISORDERS WITH
ENHANCED AVP-MEDIATED WATER
REABSORPTION AND NOVEL AVENUES
FOR THERAPY
Vaptans
Vaptans, also termed aquaretics, comprise a family of V2R
antagonists. They include intravenously administered conivaptan
and oral vaptans like tolvaptan, lixivaptan, and satavaptan
(Narayen and Mandal, 2012). Tolvaptan, the most extensively
used vaptan, selectively inhibits the binding of AVP to the V2R
with an almost two times higher affinity than AVP, and interferes
with the AQP2 redistribution into the plasma membrane of
collecting duct principal cells (Sato et al., 2014). Patients treated
with tolvaptan have increased urine AQP2 levels (Sato et al.,
2014), indicative of shedding of AQP2 from the apical plasma
membrane into the urine.
The aquaretic effect is achieved by enhanced free water
clearance without induction of natriuresis, kaliuresis or changes
of the glomerular filtration rate (Graziani et al., 2014). Vaptans
are approved for the therapy of hypervolemic (heart failure,
liver cirrhosis, SIADH) (Narayen and Mandal, 2012) and
normovolemic hyponatremia, and since recently for autosomal
dominant polycystic kidney disease (Lin et al., 2014; Blair and
Keating, 2015). In particular, the adjustment of sodium levels in
patients suffering from SIADH and hyponatremia can be easier
controlled with vaptans than with conventional hypertonic saline
infusions. This translates into a better safety profile, and a lower
risk of side effects (Nathan, 2007). Heart failure patients are
treated with conventional anti-hypertensive drugs and only since
recently additionally with V2 receptor antagonists (vaptans, see
below) if hospitalized (Gilotra and Russell, 2014). More than half
of the cirrhosis patients suffer from ascites, a major complication
associated with sodium and AVP-dependent water retention that
is characterized by the accumulation of fluid in the abdominal
cavity. Hence, V2R antagonists could prove beneficial in the
symptomatic treatment of this condition by increasing urine
output (Yan et al., 2015).
Demeclocycline
Demeclocycline, a bacteriostatic antibiotic of the tetracycline
group, is used for the treatment of sustained hyponatremia
in patients with SIADH. It is the first choice in this case
because of its aquaretic effect. Demeclocycline decreases the
AVP-induced cAMP production and abundance of adenylyl
cyclases 3 and 5/6, and reduces the expression of AQP2 in the
apical plasma membrane of mpkCCD cells without affecting the
V2R. In a rat model of SIADH, demeclocycline increased urine
volume, decreased urine osmolality and alleviated hyponatremia
as has been shown in patients (Kortenoeven et al., 2013). Other
tetracycline antibiotics including minocycline, doxycycline and
tetracycline have similar effects with regard to reducing urine
volume in toads (Feldman and Singer, 1974; Hirji and Mucklow,
1991). Tetracycline reduces urinary concentrating ability also
in humans (Wilson et al., 1973). However, demeclocycline
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(600–1200mg/day) may also cause NDI in some patients, and
that is the reason for the limited application of these drugs in





Protein-protein interactions play key roles in all biological
processes. They are diverse and highly specific and, therefore,
provide ample opportunities for the development of novel drugs
(Jones and Thornton, 1996; Klussmann and Rosenthal, 2008;
Cho et al., 2016). Since AKAP-PKA interactions are involved
in AQP2 trafficking (Klussmann et al., 1999; Klussmann and
Rosenthal, 2001), their disruption may lead to a new concept
for the treatment of diseases characterized by excessive AVP-
mediated water retention such as heart failure (Nedvetsky
et al., 2009; Tröger et al., 2012; Deak and Klussmann, 2015;
Dema et al., 2015). Indeed, peptides, peptidomimetics, and
small molecules for the non-selective disruption of AKAP-
PKA interactions are available (Hundsrucker et al., 2006a,b;
Hundsrucker and Klussmann, 2008; Christian et al., 2011;
Schäfer et al., 2013; Schächterle et al., 2015). All of these
agents target the AKAP-binding domain of regulatory R subunits
of PKA, the dimerization/docking (D/D) domain. They bind
competitively and thereby prevent the interactions of R subunits
with AKAPs (Deak and Klussmann, 2015). The peptides such as
Ht31, AKAP18-derived peptides or AKAPIS all bind R subunits
with high affinity and thereby effectively disrupt AKAP-PKA
interactions. However, short half-life, low bioavailability, and
membrane permeability limit the development of peptide-based
drugs, although several peptide-drugs reached the market (Otvos
and Wade, 2014). The available peptidomimetics are low affinity
binders and require a multistep synthesis. They would require
further optimization prior to becoming candidates for drug
development (Dema et al., 2015). Most promising are small
molecule inhibitors of protein-protein interactions. With good
bioavailability and enhanced plasma membrane permeability
they can be optimized toward effective inhibitors. However, the
development is challenging, because protein-protein interaction
interfaces are generally large and shallow and can hardly be
completely covered by small molecules. Despite this, in the
past years remarkable progress has been made and several
small molecule inhibitors of protein-protein interactions were
discovered (Sheng et al., 2015). The only small molecule
inhibiting AKAP-PKA interactions, FMP-API-1, is not suitable
for further development toward a drug candidate as it also
activates PKA (Christian et al., 2011; Yu et al., 2014).
In order to identify small molecule inhibitors of the AVP-
induced redistribution of AQP2, high-throughput screening
of small molecule libraries provides ample opportunities. A
prototypical example is a screening of 17,700 small molecules for
inhibitors of the cAMP-induced redistribution of AQP2 using
a cell-based assay (Bogum et al., 2013). This approach yielded
17 inhibitors, among them, 4-acetyldiphyllin (4-AD) a selective
blocker of V-ATPase. 4AD increased pH levels of intracellular
vesicles and caused an accumulation of AQP2 in the Golgi.
The compound prevented the PKA-induced phosphorylation of
AQP2 at S256 without affecting cAMP levels, PKA activity or
the phosphorylations of AQP2 at S261 and S269. Although the
screening approach did not yield an inhibitor of PPIs, it is
suitable for identification of small molecules that may serve as
a starting point for the development of novel drug candidates for
the therapy of disorders associated with increased AQP2 levels
(Bogum et al., 2013).
SUMMARY AND OUTLOOK
The localization of AQP2 is critical for the reabsorption of water.
If located in the plasma membrane of renal collecting duct
principal cells AQP2 facilitates water reabsorption from primary
urine. A predominant localization in the plasma membrane
contributes to excessive water retention as in heart failure,
SIADH or liver cirrhosis; vice versa a predominant intracellular
localization causes diabetes insipidus, a disease characterized by
a massive loss of hypotonic urine. A variety of cAMP-dependent
and independent signaling pathways and defined protein-protein
interactions have been identified that control the localization of
AQP2. Considering the still unmet medical need in both classes
of diseases, i.e., diseases with a high- or a low-level plasma
membrane localization of AQP2, pharmacological targeting of
the mechanisms controlling AQP2 trafficking provides ample
opportunities for the development of novel drugs.
Several established drugs modulate the localization of AQP2
in animal models, and first data from patients confirmed these
effects. Examples are statins that promote or NSAIDs and vaptans
that prevent the plasmamembrane localization of AQP2. Further
clinical trials will have to confirm the value of repurposing such
drugs toward the treatment of water balance disorders. However,
all of these established drugs cause unwanted side effects, which
may limit their use. Therefore, it will be necessary to continue
with the identification of molecular mechanisms underlying the
control of the localization of AQP2 to provide novel drug targets.
In particular, identifying protein-protein interactions that govern
the control of AQP2 is relevant as protein-protein interactions
are highly specific and diverse and therefore represent a unique
class of drug targets. AKAP-PKA interactions that are essential
for the AVP-induced redistribution of AQP2 are an example
(Christian et al., 2011; Schächterle et al., 2015). It is important
to define “hot spots” within the interacting surfaces, i.e., crucial
amino acids that mediate the interaction and that can be targeted
with small molecules for effective disruption (Buchwald, 2010;
Villoutreix et al., 2014; Sheng et al., 2015). For identifying
small molecule inhibitors of protein-protein interactions high-
throughput screening may be used. This approach has led to the
identification of FMP-API-1, the first small molecule disruptor
of AKAP-PKA interactions (Keskin et al., 2008; Christian et al.,
2011).
Other unbiased screening approaches have identified small
molecule modulators of the AVP-induced redistribution of
AQP2. The identification of the inhibitor 4AD for example
provided new insight into the regulation of AQP2. It identified
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V-ATPase as a protein involved in the control of AQP2 (Bogum
et al., 2013). Another example is the identification of a small
molecule activator of the AQP2 redistribution, AG-490. AG-
490 inhibits the EGF receptor and JAK-2 kinase (Nomura et al.,
2014). Even though targeting a ubiquitous protein such as V-
ATPase or the EGF receptor may not be an option for the
treatment of patients, the screening approaches are valuable for
the identification of new molecules and targets and may provide
new starting points for the development of novel drugs for the
treatment of water balance disorders.
Taken together, many questions surrounding water
balance disorders have been answered but even more remain
unanswered. A particular topic in the future will be to translate
the insights into molecular mechanisms underlying the
trafficking of AQP2 into novel therapies for these diseases with
their unmet medical needs.
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